DNA Adducts in Cancer Chemotherapy

Stereoselective Synthesis of ABBV-992 Enabled by a Flow Diazotization and a Partial Reduction of a Pyridone

“…Development of a direct asymmetric reductive amination or transaminase biocatalysis − process to generate 12 from 13 would provide reduced step count and could be advantageous on process scales. Use of piperazine annulation reagent 18 was convenient on lab scale, however on process scales may raise concerns of process mass intensity and toxicity …”

Celebrating the 60th Anniversary of the MIKIW Meeting-in-Miniature: Virtual Special Issue

“…Finally, in this Virtual Special Issue, you will find several diverse sets of Viewpoints and Perspectives, including a comprehensive analysis of FDA-approved drugs for cancer chemotherapy that function through DNA adducts; a Perspective on the development of peptide–drug conjugates as emerging therapeutic modalities; a Perspective highlighting Gram-negative bacteria drug design, the multifaceted approaches being employed, and current gaps in knowledge for compound development; a personal perspective from one of the early student trainees of the MIKIW meeting; and a Viewpoint from recent MIKIW Keynote speaker, Nick Meanwell, describing opportunities for exploiting the concept of target vulnerability through optimizing drug–target interactions with high levels of cooperativity …”